Chemoinformaics analysis of (3)-beta-farnesene
| Molecular Weight | 204.357 | nRot | 7 |
| Heavy Atom Molecular Weight | 180.165 | nRig | 4 |
| Exact Molecular Weight | 204.188 | nRing | 0 |
| Solubility: LogS | -5.649 | nHRing | 0 |
| Solubility: LogP | 5.663 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 39 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 15 | No. of Aromatic Carbocycles | 0 |
| nHetero | 0 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 24 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 0 | No. of Arom Bond | 0 |
| nHA | 0 | APOL | 41.053 |
| nHD | 0 | BPOL | 24.077 |
| QED | 0.395 |
| Synth | 3.062 |
| Natural Product Likeliness | 2.874 |
| NR-PPAR-gamma | 0.108 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.788 |
| Pgp-sub | 0.001 |
| HIA | 0.006 |
| CACO-2 | -4.555 |
| MDCK | 0.0000149 |
| BBB | 0.749 |
| PPB | 0.976658 |
| VDSS | 3.639 |
| FU | 0.01417 |
| CYP1A2-inh | 0.867 |
| CYP1A2-sub | 0.31 |
| CYP2c19-inh | 0.307 |
| CYP2c19-sub | 0.665 |
| CYP2c9-inh | 0.347 |
| CYP2c9-sub | 0.882 |
| CYP2d6-inh | 0.072 |
| CYP2d6-sub | 0.477 |
| CYP3a4-inh | 0.132 |
| CYP3a4-sub | 0.243 |
| CL | 7.879 |
| T12 | 0.25 |
| hERG | 0.006 |
| Ames | 0.005 |
| ROA | 0.005 |
| SkinSen | 0.962 |
| Carcinogencity | 0.276 |
| EI | 0.976 |
| Respiratory | 0.678 |
| NR-Aromatase | 0.023 |
| Antiviral | Yes |
| Prediction | 0.738961 |